CELEBREX 200MG CAPSULE contains Celecoxib which belongs to group of medicines called Non-steroidal anti-inflammatory drugs. CELEBREX 200MG CAPSULE is used in adults to manage osteoarthritis (degenerative joint disease), rheumatoid arthritis (inflammatory disease of joints), ankylosing spondylitis (chronic back pain), acute pain and primary dysmenorrhea (menstrual cramps).
CELEBREX 200MG CAPSULE is also used to manage juvenile rheumatoid arthritis (in children aged 2 years and above).
CELEBREX 200MG CAPSULE is not recommended for use in patients allergic to Celecoxib, sulfonamides, aspirin and/or other NSAIDs. It is also not recommended for use in patients with/had a history of an ulcer in stomach/intestines, bleeding in stomach/intestines, blood circulation problems (such as peripheral arterial disease), red itchy welts, inflammatory disease of the intestines (such as ulcerative colitis/Crohn’s disease).
The medicine is also not indicted for use in patients suffering from lung problems (such as asthma), heart diseases (such as heart failure, recent heart attack, heart block), severe liver disease (such as advanced hepatic insufficiency) and/or kidney disease (such as advanced renal insufficiency).
Before taking CELEBREX 200MG CAPSULE, inform your doctor if you have diabetes, raised blood pressure, increased cholesterol, signs of fluid retention (such as swollen ankles and feet) and/or hyperkalemia (increased potassium level in blood).
CELEBREX 200MG CAPSULE is not recommended for use in pregnant and breast-feeding women.
CELEBREX 200MG CAPSULE should be used with caution in children and adolescents (aged 2 to 17 years) to manage only juvenile rheumatoid arthritis and is advised to be used with caution in elderly patients (aged 65 years/above) after consulting the doctor.
The most common side effects of taking CELEBREX 200MG CAPSULE are high blood pressure, shortness of breath, sore throat, cough, headache, nausea and dizziness. Consult your doctor if any of these symptoms worsen.
ificant decrease in vision or hearing if you have to stop taking CELEBREX 200MG CAPSULECELEBREX 200MG CAPSULE may cause dizziness or nausea when not taken. It can also cause lightheadedness and fainting. Keep all your scheduled scheduled activities as normal.
Avoid sharing CELEBREX 200MG CAPSULE with others, since it may cause harm.
use of CELEBREX 200MG CAPSULE- CELEBREX 200MG CAPSULE may cause dehydration, so take care to drink plenty of water. Make sure to keep the patient informed if you are taking any other medication.
- Enhance treatment efficiency by consuming a high dose of CELEBREX 200MG CAPSULE as per schedule so that all patients are taken on time.
- Red blood cells are essential for red blood cells. It’s helpful for the the treatment of Revolutionary Warner’s disorder. - Co-ordination of medical and physical therapy with dialysis is also very helpful.
-aily anti-inflammatory medicine along with NSAIDs helps in reducing fever, swelling, and infections. - Regularly monitor heart rate, blood pressure, liver function, kidney function and condition.
warner’s disorder- NSAIDs are an anti-inflammatory medication used to treat inflammatory diseases of the stomach/intestines, ulcers and bleeding. - NSAIDs are an anti-platelet medication used to treat pain and inflammation. - In case of NSAIDs contact doctor right away if the symptoms are not improving.
Inform your doctor if you experience any other side effects besides lightheadedness and fainting. Consult doctor about other side effects.
- NSAIDs can cause fluid retention (edema) in the body. The most common side effects of taking CELEBREX 200MG CAPSULE are“” tiredness, dizziness, feeling sick, feeling hot, pain in arms and legs (back or chest), tiredness, muscle pain, irregular heartbeat, nausea and dizziness.
The U. S. Food and Drug Administration today approved a new indication for the Celebrex (celecoxib) osteoarthritis drug Celebrex (celecoxib) for non-steroidal anti-inflammatory drugs (NSAIDs), which is indicated for patients with osteoarthritis. The new indication is a new safety study for Celebrex in adults with osteoarthritis, to be published in the February issue ofThe New England Journal of Medicine.
Celebrex is an FDA-approved medication to treat painful osteoarthritis in the hand and upper extremities. Patients can expect to have their hands treated with Celebrex for 10 to 20 days, depending on their condition.
The new indication for Celebrex will also be available to patients at a reduced cost to the U. government for other drugs as well.
“This is the first safety study to determine the efficacy of Celebrex in patients with osteoarthritis,” said Dr. Steven Nissen, MD, assistant professor of medicine at the University of Pennsylvania School of Medicine and director of the Penn Center for Drug Evaluation and Research. “The results of this study will help us develop new treatments for this common condition.”
Patients taking Celebrex will be able to choose from a variety of options, including nonsteroidal anti-inflammatory drugs (NSAIDs), which work by blocking the production of prostaglandins, or by blocking the inflammatory responses that cause pain and inflammation. The drug is available by prescription only, so patients can have it delivered directly to their doorsteps without a doctor’s approval.
“The FDA will continue to study Celebrex for its effectiveness in reducing pain and inflammation in patients with osteoarthritis,” said Dr. Thomas W. Lechleiter, MD, director of the FDA’s Center for Drug Evaluation and Research. “This study will help the agency to determine whether Celebrex is a viable option for patients who may need long-term treatment with other pain medications.”
The new indication for Celebrex is an indication for non-steroidal anti-inflammatory drugs (NSAIDs) that can be administered orally or topically as a capsule or a tablet.
Celebrex is available by prescription only. The FDA continues to study Celebrex for its effectiveness in reducing pain and inflammation.
For more information on Celebrex, including its uses, see.
More information:
Celebrex is indicated to relieve moderate to severe pain, to reduce the risk of acute osteoarthritis, and to reduce the risk of postoperative pain.The drug is available for treatment of moderate to severe pain, as well as for the prevention of postoperative pain, including postoperative pain following surgery. The drug is indicated for the treatment of acute musculoskeletal pain, to decrease the likelihood of orthopedic surgery, to reduce the risk of postoperative pain, and to reduce the risk of postoperative pain. Celebrex is indicated for the treatment of acute pain following surgery and for the prevention of pain following surgery. Celebrex is indicated for the treatment of moderate to severe pain, as well as for the prevention of pain, as an adjunct therapy to nonsteroidal anti-inflammatory drugs. A maximum of six weeks of treatment is required for Celebrex for moderate to severe pain.
Celebrex is indicated for the treatment of acute pain following surgery and for the prevention of pain following surgery, as an adjunct therapy to nonsteroidal anti-inflammatory drugs. The recommended dosage of Celebrex is 2.5 mg to 5 mg. Patients should take Celebrex 1 to 3 hours before and 2 to 4 hours after oral or topical administration.
Important Safety Information:
Oral Celebrex is not recommended for use in children.
The safety of Celebrex has not been evaluated in children. However, pediatric patients are not advised to take any pediatric medication that contains Celebrex.
About Adverse Reactions
About 4,500 NSAID users in the U. have had one or more of these adverse reactions reported each year in patients treated with prescription drugs. Most of the adverse reactions (less than 1%) occurred in patients who had been taking prescription drugs for at least 1 year. Adverse reactions can be mild or serious.
At least one major drug manufacturer has taken the drug Celebrex® in the past year, citing safety concerns for patients taking the drug. The drug is known to cause severe gastrointestinal distress in some patients.
But the new study inNew England Journal of Medicineshows that Celebrex® — a COX-2 inhibitor — can cause severe gastrointestinal distress in patients with COX-2 disease.
In the new study, patients taking Celebrex had an increased risk of stomach and duodenal ulcers when compared to patients taking a placebo.
The study authors say their findings are important because patients taking Celebrex may not be as likely to develop GI ulcers as those who have already been on the drug.
The study, published in the, involved more than 500 patients. It was a randomized, double-blind, placebo-controlled clinical trial.
Researchers were blinded to whether patients were taking Celebrex or another nonsteroidal anti-inflammatory drug (NSAID), known as celecoxib, which is a COX-2 inhibitor.
When the researchers took their new results to a New England Journal of Medicine clinical trial, they found that Celebrex and placebo had no effect on ulcer risk.
Patients who took Celebrex had a reduced risk of developing a stomach and duodenal ulcers when compared to those who took a placebo.
“These findings are significant and warrant further investigation,” the study authors wrote.
They said the drug can cause serious gastrointestinal distress if it is taken long-term, such as if patients develop ulcers or bleeding problems.
“We have no indication that the long-term use of the drug is associated with gastrointestinal distress,” they added.
The study was conducted by the manufacturer of Celebrex. However, the company has since withdrawn from the market.
Celebrex is not expected to be the first drug to be recalled by the manufacturer over its COX-2 inhibitor use.
In March, the manufacturer announced that it planned to recall all of its products. The company will begin selling the drug at a discount to consumers.
In addition, the maker of Celebrex, Merck, has said it will temporarily recall all of its Celebrex drug products.
The warning has prompted a series of lawsuits. In October, the FDA issued a warning about Celebrex, saying the drug is not intended for long-term use. In addition, the FDA has asked Merck and other drug makers to withdraw warnings to patients with stomach ulcers.
In the study, the researchers looked at the results of more than 500 patients who took Celebrex for 12 weeks and then again at a later time after switching from the drug to a placebo. They found no increased risk of stomach and duodenal ulcers.
Patients who took Celebrex had a lower risk of gastrointestinal ulcers than those who took a placebo, the researchers said.
But they found that patients who took Celebrex had a reduced risk of a more serious condition called gastric or duodenal ulcers. Those who took the drug had a lower risk of developing these problems, and they also had lower rates of serious gastrointestinal bleeding.
They also found that the drug caused severe gastrointestinal distress and the risk of GI ulcers in more than 50 percent of patients.
“When we looked at this data, we found that there was a statistically significant increase in serious gastrointestinal distress,” the study authors wrote.
Their research also found that the drug had a “significantly higher risk of causing severe gastrointestinal distress in patients taking celecoxib than in patients who had not taken celecoxib,” they added.
In addition to the study, the FDA asked Merck to stop selling Celebrex and to conduct a clinical trial, the FDA said.
The drugmaker had announced that it would temporarily recall all of its Celebrex products.
But the company has since withdrawn from the market.
Merck said it will continue to sell Celebrex to patients in the United States. The company has also removed its Celebrex drug products from its consumer product catalog.
The FDA will continue to monitor the safety of the drug, it added. The agency said it expects the new study to provide valuable information for healthcare providers and patients.
Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Medicare CardNo MedicareConcession
$8.95
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
ThisPrivacy This Medsagreement involves a number of separate, disagrees-through-ways that require neither sides to determine the amount of money the bargain is madeHealthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews
Healthylife is an independently owned and operated pharmacy business, which uses only the privacy of its own skin, wallet and purse. The only contact information being provided is with a pharmacist. If you have questions about this agreement, please don't hesitate to contact your healthcare provider.medicare agreement involves a number of separate, disagree-through-ways that require neither sides to determine the amount of money the bargain is made. This agreement involves a number of separate, disagree-through-ways that require neither sides to determine the amount of money the bargain is made.
Stade de France Pharmacy